• Int J Obstet Anesth · Dec 2018

    Remifentanil patient-controlled analgesia in labour: six-year audit of outcome data of the RemiPCA SAFE Network (2010-2015).

    In women receiving a remifentanil PCA for labour analgesia, detectable hypoxia occurs in 25% of women and neonatal CPR potentially related to remifentanil in 1 in 300 babies.

    pearl
    • A A Melber, Y Jelting, M Huber, D Keller, A Dullenkopf, T Girard, and P Kranke.
    • Department of Anaesthesiology, Spital Münsingen, Insel Gruppe AG, Münsingen, Switzerland. Electronic address: andrea.melber@remipca.org.
    • Int J Obstet Anesth. 2018 Dec 21.

    BackgroundThe RemiPCA SAFE Network was established to set standards and monitor maternal and neonatal outcomes when using remifentanil for labour analgesia. The aim of this analysis was to describe the development of the network standard and to report maternal and neonatal outcome data, including severe adverse events.MethodsData sets of the RemiPCA SAFE Network database from the initial six consecutive years (2010-2015) were retrospectively analysed. The data were analysed on an annual basis and set in context with changes of the network standard, i.e. adaptations of the network's standard operating procedure. Main outcomes reported are maternal and neonatal data regarding effectiveness and safety, such as satisfaction, need for bag/mask ventilation and/or cardiopulmonary resuscitation.ResultsAmong 5740 data sets, no need for maternal ventilation or cardiopulmonary resuscitation was registered. Neonatal cardiopulmonary resuscitations, potentially related to remifentanil, occurred in 0.3%. In parallel with adaptations of the network standard, a moderate rate of maternal hypoxia (oxygen saturation <94% in 24.7%) was found, together with a low rate of supplemental oxygen requirement in neonates (5.0%).ConclusionThe RemiPCA SAFE Network data show that remifentanil patient-controlled analgesia can be applied safely. There is bias when data from real clinical settings are analysed retrospectively. Notwithstanding, the approach taken by the RemiPCA SAFE Network, with constant, systematic and standardised evaluation of multiple parameters during the course of labour, might identify trends and anomalies and guide the development and application of safety standards, when translating knowledge from scientific trials into clinical practice.Copyright © 2018 Elsevier Ltd. All rights reserved.

      Pubmed     Full text  

      Add institutional full text...

    This article appears in the collection: Is remifentanil for labour analgesia safe and effective?.

    Notes

    pearl
    1

    In women receiving a remifentanil PCA for labour analgesia, detectable hypoxia occurs in 25% of women and neonatal CPR potentially related to remifentanil in 1 in 300 babies.

    Daniel Jolley  Daniel Jolley
     
    Do you have a pearl, summary or comment to save or share?
    250 characters remaining
    help        
    You can also include formatting and links in your notes
    • Simple formatting can be added to notes, such as _italic_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)

    hide…